ライフサイエンスコーパス: PET imaging

1 -Pittsburgh compound B (PiB) and 18F-MK-6240 PET imaging.

2 n between phosphorylated tau in CSF with tau PET imaging.

3 cult in some patients referred for (18)F-FDG PET imaging.

4 ivo binding in the rat, and nonhuman primate PET imaging.

5 ion and quantification of this protein using PET imaging.

6 asible and should be considered for coronary PET imaging.

7 ted to confirm engrafted islet numbers after PET imaging.

8 ed data were correlated with tumor uptake by PET imaging.

9 tumors, as demonstrated by RGD-based in vivo PET imaging.

10 ilability was indexed using [(11)C]Ro15-4513 PET imaging.

11 inhibitors via noninvasive and quantitative PET imaging.

12 Antibodies are promising vectors for PET imaging.

13 d MRI as well as (11)C-PiB and (18)F-MK-6240 PET imaging.

14 nge and cognitive change, using flortaucipir PET imaging.

15 tivity MRI (fcMRI) in the context of amyloid-PET imaging.

16 s-3 HABs, 3 MABs, and 2 LABs-underwent brain PET imaging.

17 ng PDE4B-preferring radioligand for clinical PET imaging.

18 value was determined with the HEC method at PET imaging.

19 racer for investigating tumor perfusion with PET imaging.

20 h(Hor)-dAph(Cbm)-Lys-Thr-Cys)-dTyr-NH2)) for PET imaging.

21 s synthesized to incorporate fluorine-18 for PET imaging.

22 ed the feasible application of (64)Cu(I) for PET imaging.

23 ghrelin receptor expressing carcinomas using PET imaging.

24 orination, autoradiography, and small-animal PET imaging.

25 as (225)Ac and (227)Th are incompatible with PET imaging.

26 18)F-rhPSMA-7.3 are considered favorable for PET imaging.

27 8) F radionuclide incorporation required for PET imaging.

28 f clinical sites that can perform diagnostic PET imaging.

29 logy with MIBG and the general advantages of PET imaging.

30 iable quantification of neuroinflammation by PET imaging.

31 mbrane antigen [PSMA]) is a novel ligand for PET imaging.

32 e scanned repeatedly with [(11)C]carfentanil PET imaging.

33 nflammatory leukocyte signal using (18)F-FDG PET imaging.

34 ith [(11)C]PiB positron emission tomography (PET) imaging.

35 radioprobe for positron emission tomography (PET) imaging.

36 )Y tracers for positron emission tomography (PET) imaging.

37 diotracers for positron emission tomography (PET) imaging.

38 [(11)C]PK11195 positron emission tomography (PET) imaging.

39 flammation was assessed using [(11)C]PK11195 PET imaging, a marker of microglial activation.

40 subset of patients with interval metabolic (PET) imaging after initial chemotherapy, complete metabo

41 f [(89)Zr]Zr-DFO-scFv-Fc-CD44 as a versatile PET imaging agent for patients with CD44-positive tumors

42 CDKi) was evaluated and validated as a novel PET imaging agent to quantify CDK4/6 expression in estro

43 JR11 is under clinical development as a PET imaging agent when labeled with (68)Ga ((68)Ga-NODAG

44 prostate-specific membrane antigen (rhPSMA) PET imaging agent, (18)F-rhPSMA-7.3.

45 on the uptake by tumor cells of (18)F-FDG, a PET imaging agent.

46 and brain uptake of the corresponding (64)Cu PET imaging agent.

47 g to develop a positron emission tomography (PET) imaging agent for the GluN2B subunits of the N-meth

48 eport a (64)Cu positron emission tomography (PET) imaging agent that shows appreciable in vivo brain

49 ium, and its role in drugs for radiotherapy, PET imaging agents and perspectives for applications in

50 ose within the acceptable range for clinical PET imaging agents and the potential for translation int

51 Previously reported PET imaging agents targeting CXCR4 suffer from either hi

52 uitable for further development as oncologic PET imaging agents.

53 uture academically sponsored NDA filings for PET imaging agents.

54 PET imaging allowed us to identify the compound [(68)Ga]

55 Conclusion: (18)F-BMS-986192 PET imaging allows detection of membrane-expressed PD-L1

56 PET imaging allows dynamic observation of the bio-distri

57 igated whether positron emission tomography (PET) imaging allows identification of altered metabolic

58 ing and rapid normal tissue clearance of the PET imaging analog (86)Y-NM600.

59 thods: NM600 was radiolabeled with (86)Y for PET imaging and (177)Lu for targeted radionuclide therap

60 PET imaging and biodistribution studies showed fast clea

61 PET imaging and biodistribution studies showed high tumo

62 PET imaging and biodistribution studies showed that the

63 on their in vitro performance, small-animal PET imaging and biodistribution studies were performed o

64 For PET imaging and biodistribution studies, a C4-2 tumor-be

65 PET imaging and biodistribution were performed 24 h afte

66 evaluating the prognostic value of (18)F-FDG PET imaging and compared it with histologic grading.

67 e as radiochemical twins for both diagnostic PET imaging and endoradiotherapy.

68 PET imaging and ex vivo autoradiography revealed more pa

69 ect utility of this protocol for preclinical PET imaging and its translation to automated radiosynthe

70 facilitate a personalized medicine approach, PET imaging and quantification of mAbs, after chelation

71 stably be labeled with (89)Zr for whole-body PET imaging and quantification.

72 t acquisition and high spatial resolution of PET imaging and the intense uptake in tumor lesions, fac

73 n low-molecular-weight PSMA ligands for both PET imaging and therapeutic approaches, with a focus on

74 2 and 3 position as potential candidates for PET imaging and/or therapy.

75 o, we employed positron emission tomography (PET) imaging and biodistribution studies in multiple xen

76 apy (PDT) with positron emission tomography (PET) imaging and internal radiotherapy (RT).

77 (high density EEG and 18F-fluorodeoxyglucose PET imaging) and structural (diffusion tensor imaging MR

78 ofiles and pharmacokinetics are suitable for PET imaging, and absorbed dose estimates are comparable

79 nd FLAIR volumetric MRI, florbetapir amyloid-PET imaging, and cognitive assessment at University Coll

80 , subjects also received florbetapir amyloid PET imaging, and underwent a neuropsychological test bat

81 ND AND Amyloid-positron emission tomography (PET) imaging (API) detects amyloid-beta pathology early

82 highlights the potential utility of the OX40 PET imaging as a new strategy for GvHD diagnosis and the

83 to detect tau pathology in AD patients using PET imaging, as well as to assess its safety and tolerab

84 to detect tau pathology in AD patients using PET imaging, as well as to assess the safety and tolerab

85 n = 13) followed by dual MEMRI and (18)F-FDG PET imaging at 10-12 weeks.

86 PET imaging at 8 wk post-AAV delivery showed an increase

87 PET imaging at late time points after injection may allo

88 PET imaging at multiple time points (0-72 h) was perform

89 PET imaging-based estimates were less variable and more

90 They all underwent [F-18]-AV-1451 PET imaging before death.

91 PET imaging, biodistribution, autoradiography and immuno

92 tion was performed in Wistar rats comprising PET imaging, biodistribution, receptor occupancy, and me

93 uld serve as a positron emission tomography (PET) imaging biomarker for HD therapeutic development an

94 d emerging conventional nuclear medicine and PET imaging biomarkers, as the diagnostic nuclear medici

95 ionuclides for positron emission tomography (PET) imaging, but also capture the potentially released

96 Overall, our results suggest granzyme B PET imaging can serve as a quantitatively useful predict

97 ng (64)Cu(2+), positron emission tomography (PET) imaging can be achieved for in vivo real-time and q

98 and its (134)La daughter) could be used as a PET imaging candidate for (225)Ac(III) (with reduced (13

99 PET imaging confirmed excellent tumor specificity for [(

100 Immuno-PET imaging confirmed in vivo antigen-specific targeting

101 Dynamic PET imaging confirmed PSMA-specific (as demonstrated by

102 ic vesicle glycoprotein 2A radiotracers with PET imaging could provide a way to measure synaptic dens

103 (64)Cu-Macrin PET imaging could stage inflammatory cardiovascular dise

104 previously acquired human [(11)C]carfentanil PET imaging data (132 male and 72 female healthy subject

105 We examined the PET imaging data of serotonin transporter occupancy by S

106 te tumor accumulation was EGFR-specific, and PET imaging data showed a clear differentiation between

107 earning algorithm to a multiparametric brain PET imaging dataset acquired in a cohort of 20- to 82-ye

108 18F-DOPA PET imaging demonstrated a significantly increased uptak

109 Small-animal PET imaging demonstrated high tumor uptake within 20 min

110 Performing PET imaging during ongoing radionuclide therapy can be a

111 The use of (18)F-BnTP PET imaging enabled us to functionally profile mitochond

112 PET imaging enables investigation, quantification, and t

113 in Wistar rats by in vitro autoradiography, PET imaging, ex vivo biodistribution, metabolite experim

114 Subsequent radiolabelling and in vivo PET imaging experiments in a small animal model demonstr

115 ensus by 2 experienced oncologists masked to PET imaging findings, was used as a reference standard.

116 re use in vivo positron emission tomography (PET) imaging, flow cytometry, and confocal microscopy to

117 ontrols (HC) underwent dynamic (18)F-PI-2620 PET imaging for 180 min.

118 ntrols (HCs) underwent dynamic (18)F-PI-2620 PET imaging for 180 min.

119 bicentric pivotal phase 3 clinical trial for PET imaging for prostate cancer.

120 the long-term prognostic value of (18)F-FDG PET imaging for risk stratification of NENs and compare

121 spected Alzheimer disease) underwent dynamic PET imaging for up to 120 min after bolus injection of (

122 (89)Zr-MSB0010853 PET imaging gives insight into the in vivo behavior of M

123 Somatostatin receptor PET imaging has had a profound effect on the evaluation

124 ed that chelator-mediated nanoparticle-based PET imaging has its inherent drawbacks and can possibly

125 Tau PET imaging has potential for elucidating changes in the

126 [(18)F]FDOPA PET imaging has shown dopaminergic function indexed as K

127 PET imaging has the potential to detect striatal molecul

128 ose positron emission tomography ([(18)F]FDG-PET) imaging has an essential role in diagnosing DLBCL i

129 ards this end, positron emission tomography (PET) imaging has emerged as one of the most informative

130 PET imaging identified significantly higher left ventric

131 ATATE PET imaging was compared to [(18)F]FDG PET imaging in 42 patients with atherosclerosis.

132 t promising compounds were used for clinical PET imaging in 8 cancer patients.

133 chizophrenia patients using [(11)C]Ro15-4513 PET imaging in a cross-sectional, case-control study des

134 Conclusion: Using (18)F-flortanidazole PET imaging in a non-small cell lung cancer xenograft mo

135 y, we measured tau accumulation using AV1451 PET imaging in a subset of 87 participants.

136 )Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.

137 quent longitudinal change in Abeta using PIB-PET imaging in cognitively normal older adults.

138 the effect of AB treatment on (68)Ga-PSMA-11 PET imaging in hormone-naive (luteinizing hormone-releas

139 PET imaging in mice showed specific uptake of (18)F-olap

140 radiotracer, with optimized brain uptake by PET imaging in nonhuman primates.

141 ly seen on interictal 18F-fluorodeoxyglucose PET imaging in patients with focal epilepsy-that inheren

142 essed the feasibility of using (18)F-SKI for PET imaging in patients with malignancies.

143 halamus, and hippocampus was demonstrated by PET imaging in rodents.

144 verview on the current status of PSMA ligand PET imaging, including imaging procedure and interpretat

145 PET imaging is a sensitive and clinically relevant modal

146 he [18F]AV-1451 signal as seen on results of PET imaging is a valid marker of clinical symptoms and n

147 e-specific membrane antigen (PSMA)-targeting PET imaging is becoming the reference standard for prost

148 Conclusion: GPM during coronary (18)F-NaF PET imaging is common and may affect quantitative accura

149 he potential diagnostic utility of (18)F-FES PET imaging is expected to be equally valid for patients

150 However, small-animal PET imaging is limited by coarse spatial resolution.

151 for diagnostic scintigraphy, especially when PET imaging is not available.

152 ts for HER2-targeting therapy in areas where PET imaging is not readily available.

153 imaging tools such as (89)Zr-Df-IAB22M2C for PET imaging is of prime importance to identify patients

154 lar and pathological processes on which TSPO PET imaging is reporting.

155 (18)F-FDG PET imaging is routinely used to investigate brown adipo

156 In vivo positron emission tomography (PET) imaging is a key modality to evaluate disease statu

157 Therefore, [(11)C]13 is a potential PET imaging ligand for mGluR2 in different central nervo

158 d as potential positron emission tomography (PET) imaging ligands for mGluR2 in the brain.

159 ive neuropsychological assessments following PET imaging (mean number of cognitive visits = 2.8 +/- 1

160 mendous efforts have been made in developing PET imaging methods for pediatric brain tumors.

161 The (18)F-MAPP PET imaging noninvasively differentiated varying amounts

162 By using PET imaging of (18)F-BnTP, we profile mitochondrial memb

163 adiation dose from whole-body (11)C-nicotine PET imaging of 11 healthy (5 male and 6 female) subjects

164 For PET imaging of 18-kDa translocator protein (TSPO), a bio

165 We could also utilize PM-PBB3 for optical/PET imaging of a living murine tauopathy model.

166 PET imaging of amino acid transport using O-(2-(18)F-flu

167 Abeta) aggregates, leading to the successful PET imaging of amyloid plaques in the brains of 5xFAD mi

168 Finally, small-animal PET imaging of an LNCaP tumor-bearing mouse was performe

169 Methods: We developed and validated brain PET imaging of awake, freely moving mice.

170 Bioluminescence and PET imaging of B7H3-sr39tk CAR T cells confirmed complet

171 s changes in neural circuitry (measured with PET imaging of cerebral glucose metabolism at baseline a

172 abeled lipophilic cations being used for the PET imaging of chemotherapy-induced cardiotoxicity and i

173 Conclusion: (11)C-PS13 shows promise for PET imaging of COX-1 in OvCa, and rapid translation for

174 ant models that indicate potential for human PET imaging of CSF1R and the microglial component of neu

175 is suitable for noninvasive, highly specific PET imaging of CXCR4 expression in the atherosclerotic a

176 (HC) participants completed [(11)C]-(+)-PHNO PET imaging of D2R and D3R availability and fMRI during

177 a-labeled FAP inhibitor ((68)Ga-FAPI-04) for PET imaging of fibroblast activation in a preclinical mo

178 (A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients wi

179 y be clinically relevant and exploitable for PET imaging of galectin-1-overexpressing bladder tumors.

180 Core body temperature, PET imaging of glucose uptake and VO(2) measurements con

181 ising candidate for preclinical and clinical PET imaging of hNIS expression and thyroid-related disea

182 to be the first appropriate radiotracer for PET imaging of human M(1) AChR.

183 tegrin recognition sequence that facilitates PET imaging of integrin upregulation during tumor angiog

184 uated an agonist tracer, (11)C-GR103545, for PET imaging of KOR in humans.

185 antagonist (11)C-LY2795050 radiotracers for PET imaging of KOR in humans.

186 nd metabolism in HCCs were analyzed by micro-PET imaging of mice; livers were collected and analyzed

187 nstrate successful CD38-targeted immunologic PET imaging of multiple myeloma in a murine model and in

188 , or (89)Zr-DFO-daratumumab, for immunologic PET imaging of multiple myeloma.

189 Furthermore, although PET imaging of neuroinflammation does not have an establ

190 This work advances PET imaging of NK cells and supports the translation of

191 PET imaging of PDE4 with (11)C-(R)-rolipram has been use

192 that are (18)F-labeled in a single step for PET imaging of prostate cancer.

193 nd Drug Administration as the first drug for PET imaging of prostate-specific membrane antigen (PSMA)

194 Here, we demonstrate such a method using PET imaging of radiolabeled bevacizumab.

195 4)Cu]Cu-DOTATATE and [(68)Ga]Ga-DOTATATE for PET imaging of somatostatin receptor-expressing tumors,

196 PET imaging of tau pathology in Alzheimer disease may be

197 PET imaging of the 18-kDa translocator protein (TSPO) pr

198 )F-DPA-714 is a second-generation tracer for PET imaging of the 18-kDa translocator protein (TSPO), a

199 PET imaging of translocator protein 18 kDa (TSPO) permit

200 din-4 was radiosynthesized and evaluated for PET imaging of transplanted human islets in the liver of

201 rs (FAPIs) have been successfully applied to PET imaging of various tumor types.

202 FAP is a new target molecule for PET imaging of various tumors.

203 Positron emission tomography (PET) imaging of the 18 kDa translocator protein (TSPO),

204 Conclusion: The present method enables brain PET imaging on awake mice, thereby avoiding the confound

205 PET imaging on both scanners consisted of a list-mode ac

206 reduced scan duration in oncologic (18)F-FDG PET imaging on quantitative and subjective imaging param

207 gh compound B) and tau ((18) F-flortaucipir) PET imaging on the same participants.

208 In two studies using PET imaging, one empirical (Study 1: N = 144 males and f

209 xtensive simulation studies, the analyses of PET-imaging outcomes from the Alzheimer's Disease Neuroi

210 g that 1-L-[(18)F]FETrp may prove a valuable PET imaging probe for the Shh subgroup of medulloblastom

211 oethyl)-L-tryptophan (1-L-[(18)F]FETrp) as a PET imaging probe for this common malignant pediatric br

212 tiomers of (11)C-Me-NB1, a recently reported PET imaging probe that targets the GluN2B subunit of N-m

213 We designed novel PET imaging probes for the murine and human granzyme B i

214 elled tryptophan derivatives are feasible as PET imaging probes in brain tumor patients with activati

215 Coronary PET imaging protocols require scans of up to 30 min, int

216 [(18)F]FSPG PET imaging provides a sensitive noninvasive measure of

217 tate-specific membrane antigen (PSMA)-ligand PET imaging provides unprecedented accuracy for whole-bo

218 In 5-day-old mice, (64)Cu-Macrin PET imaging quantified physiologically more numerous car

219 are currently successfully used for clinical PET imaging, radionuclide therapy, and radioguided surge

220 hould be further studied to evaluate it as a PET imaging radiotracer.

221 te-specific membrane antigen (PSMA)-targeted PET imaging recently emerged as a new method for the sta

222 low in a set of specific brain regions using PET imaging, recently nearly all studies on the DMN empl

223 f serving the dual role both as an effective PET imaging reporter and as a suicide switch for CAR T c

224 In line with its preclinical data, PET imaging resulted in clear visualization of the cance

225 CD8-IHC confirmed the PET imaging results.

226 (18)F-FDG PET imaging reveals over-activation induced metabolic ch

227 Results: PET imaging showed consistent tumor accumulation and ret

228 In vivo PET imaging showed specific uptake in PSMA-expressing tu

229 (18)F-FDG PET imaging shows these changes are accompanied by alter

230 s with LVV (n = 69) underwent 141 paired FDG-PET imaging studies at one and two hours per a delayed i

231 ptor occupancy studies and has potential for PET imaging studies in ALS patients and possibly other b

232 PET imaging studies in rats demonstrated that [(11)C]13

233 as well as in vivo biodistribution and brain PET imaging studies in wildtype and mGluR2 knockout rats

234 PET imaging studies in Wistar rats showed a similar hete

235 Biodistribution and small-animal PET imaging studies were performed in CB17 SCID and LNCa

236 PET imaging studies with (11)C-labeled 1 in both HD mice

237 In subsequent non-human primate (NHP) PET imaging studies, [(18)F]8 showed rapid brain uptake

238 In nonhuman primate PET imaging studies, dose-dependent receptor occupancy o

239 eparately to categorize responders in CT and PET imaging studies.

240 cholinesterase positron emission tomography (PET) imaging studies implicate cholinergic changes as si

241 rom a previous positron emission tomography (PET) imaging study in epilepsy with 18F-FA-85380, a spec

242 aim of this work was to explore (132)La as a PET imaging surrogate for (225)Ac using a DOTA-based, tu

243 nd shape features are the least sensitive to PET imaging system variations.

244 minimize radiomic feature variations across PET imaging systems.

245 The results suggest that novel PET imaging techniques can be applied to inform and opti

246 cterize a specific small-molecule tracer for PET imaging that binds with high affinity to GPIIb/IIIa

247 maceutical for positron emission tomography (PET) imaging that is used to image Parkinson's disease,

248 [(11)C]Biotin PET imaging therefore provides a dynamic in vivo map of

249 is rapid dichotomous response on (68)Ga-PSMA PET imaging to AB-dependent on the presence of a hormone

250 view should be below 3.3 GBq at the time of PET imaging to avoid deadtime losses for this scanner.

251 n grade II-IV glioma who underwent (18)F-FET PET imaging to distinguish between TP and TRCs.

252 t this hypothesis, we used RGD-based in vivo PET imaging to evaluate wild-type (wt) and SHARPIN-defic

253 The use of (89)Zr-antibody PET imaging to measure antibody biodistribution and tiss

254 In this study, we used PET imaging to study the pharmacokinetics and tumor deli

255 labeled pH-targeted peptide can be used as a PET imaging tool to assess therapy response within PDAC

256 aration of the positron-emission tomography (PET) imaging tracer 3'-deoxy-3'-fluorothymidine (FLT) fr

257 Conversely, PET imaging using (124)I showed background accumulation

258 PET imaging using (64)Cu-Macrin faithfully reported accu

259 c accumulation in TF-positive BXPC-3 tumors, PET imaging using (89)Zr-Df-ALT-836 promises to open new

260 We sought to explore if PET imaging using hydrophobic cyclic peptides that parti

261 Human PET imaging using the second-generation TSPO radiotracer

262 ilability with positron emission tomography (PET) imaging using the mGlu5 receptor-specific radiotrac

263 EGFR-targeting positron emission tomography (PET) imaging using U87 tumor xenograft mouse model.

264 Serial PET imaging was carried out over 8 wk to assess PKM2 exp

265 (68)Ga-DOTATATE PET imaging was compared to [(18)F]FDG PET imaging in 42

266 city, and time between initial treatment and PET imaging was evaluated.

267 city, and time between initial treatment and PET imaging was evaluated.

268 In assessing response to therapy, FDG-PET imaging was performed at baseline and +4 days follow

269 In assessing response to therapy, (18)F-FDG PET imaging was performed at baseline and 4 d after ther

270 (86)Y-NM600 PET imaging was performed on female BALB/C mice bearing

271 Subsequently, PET imaging was performed on immunodeficient mice xenogr

272 Methods: PET imaging was performed on rhesus monkeys at baseline

273 PET imaging was performed with the KOR selective agonist

274 PET imaging was used to evaluate the whole-body distribu

275 ewly available positron emission tomography (PET) imaging, we examined whether a well-validated measu

276 and microdosed positron emission tomography (PET) imaging, we identified a series of highly potent, s

277 mpound-B (PiB) positron emission tomography (PET) imaging, we measured tau and Abeta in 124 cognitive

278 MR and (18)F-FET PET imaging were performed at baseline and after the sec

279 Mayo Clinic Study of Aging who underwent PiB PET imaging were studied.

280 PET imaging, whole-body probe counts, and blood draws we

281 Conclusion: PET imaging with (11)C-methionine specifically identifie

282 Conclusion: PET imaging with (11)C-methionine specifically identifie

283 r (131)I-omburtamab therapy underwent immuno-PET imaging with (124)I-8H9 followed by (131)I-8H9 antib

284 Conclusion: PET imaging with (124)I-omburtamab antibody administered

285 PET imaging with (18)F-FDG followed by mathematic modeli

286 Fifty-two patients with HCC underwent PET imaging with (18)F-fluorodeoxyglucose, followed by (

287 PET imaging with (68)Ga-DOTA-E[c(RGDfK)](2) peptide at d

288 ld of theranostics now uses newer SSTR-based PET imaging with (68)Ga-DOTATATE or (68)Ga-DOTATOC as a

289 PET imaging with 18-kDa translocator protein (TSPO) enab

290 Using PET imaging with a radiotracer specific for the serotoni

291 disease; it is the first example of in vivo PET imaging with a tracer containing an S-(18)F bond.

292 PET imaging with amino acid tracers in adults increases

293 a first look at the relationship between Tau-PET imaging with F(18)-AV1451 and functional connectivit

294 PET imaging with radiolabeled drugs provides information

295 iously demonstrated the potential utility of PET imaging with the dopamine D(2) and D(3) receptor ago

296 explored for different tumor entities using PET imaging with the fibroblast activation protein inhib

297 ll lung cancer xenograft tumor hypoxia using PET imaging with the hypoxia tracer (18)F-flortanidazole

298 n humans using positron emission tomography (PET) imaging with the novel KOR agonist radiotracer [(11

299 y to increase the throughput of small-animal PET imaging without considerable loss of image quality o

300 We tested whether (18)F-fluoroestradiol PET imaging would elucidate the pharmacodynamics of comb